Trial Profile
Clinical protocol for a Phase 1, randomized, double-blind, placebo-controlled, sequential-panel, ascending single-dose study to evaluate the safety, tolerability, and pharmacokinetics of CMX-020 in healthy male and female subjects.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs CMX 020 (Primary)
- Indications Neuropathic pain; Postoperative pain
- Focus Adverse reactions
- 04 Jul 2016 New trial record